

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力農本方有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

## **POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 30 MAY 2023**

Reference is made to the notice of the annual general meeting (the “**AGM Notice**”) of PuraPharm Corporation Limited (the “**Company**”) and the circular of the Company both dated 27 April 2023. The board of directors (the “**Board**”) of the Company is pleased to announce that at the annual general meeting held on Tuesday, 30 May 2023 at 10:00 a.m. (the “**AGM**”), the proposed resolutions nos. 1–6 as set out in the AGM Notice were duly passed as ordinary resolutions by the shareholders of the Company (the “**Shareholders**”) by way of poll. The poll results in respect of all the resolutions proposed at the AGM were as follows:

<b>ORDINARY RESOLUTIONS</b>		<b>Total number of votes</b>	<b>Number of votes (%)</b>	
			<b>For</b>	<b>Against</b>
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors of the Company (the “ <b>Directors</b> ”) and the auditor of the Company for the year ended 31 December 2022.	209,727,421	209,726,421 (99.999523%)	1,000 (0.000477%)

ORDINARY RESOLUTIONS		Total number of votes	Number of votes (%)	
			For	Against
2.	(a) To re-elect Mr. Ho Kwok Wah, George as an independent non-executive Director.	209,727,421	209,726,421 (99.999523%)	1,000 (0.000477%)
	(b) To re-elect Dr. Leung Lim Kin, Simon as an independent non-executive Director.	209,727,421	209,726,421 (99.999523%)	1,000 (0.000477%)
	(c) To authorise the board of Directors to fix the Directors' remuneration.	209,726,921	209,726,921 (100.000000%)	0 (0.000000%)
3.	To re-appoint Ernst & Young as auditor of the Company to hold office until conclusion of the next annual general meeting and to authorise the board of Directors to fix the auditor's remuneration.	209,727,421	209,727,421 (100.000000%)	0 (0.000000%)
4.	To give a general mandate to the Directors to buy back shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	209,727,421	209,727,421 (100.000000%)	0 (0.000000%)
5.	To give a general mandate to the Directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	209,727,421	209,727,421 (100.000000%)	0 (0.000000%)
6.	To extend the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company by the aggregate number of the shares bought back by the Company pursuant to the mandate granted by resolution 4.	209,727,421	209,727,421 (100.000000%)	0 (0.000000%)

The description of the above resolutions is by way of summary only. The full text of such resolutions appears in the AGM Notice of the Company dated 27 April 2023.

As the majority of the votes were cast in favour of the resolutions nos. 1–6, the resolutions nos. 1–6 were duly passed as ordinary resolutions of the Company.

As at the date of the AGM, the total number of issued shares of the Company was 395,897,275 shares, which was the total number of shares entitling the shareholders of the Company to attend and vote for or against on all the resolutions at the AGM. There were no shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and no Shareholder was required to abstain from voting at the AGM under the Listing Rules. There were no restrictions on any Shareholders casting votes on any of the proposed resolutions at the AGM. No Shareholder had stated his or her intention in the circular of the Company dated 27 April 2023 to vote against or to abstain from voting on any of the resolutions at the AGM.

The Company’s Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

The following Directors attended the AGM, namely Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola, Dr. Norimoto Hisayoshi, Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.

By Order of the Board  
**PuraPharm Corporation Limited**  
**Chan Yu Ling, Abraham**  
*Chairman*

Hong Kong, 30 May 2023

*Following the conclusion of the AGM, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*